AI and Cancer Research ── Colorectal ── 2026-11-19
Colorectal cancer: screening, treatment, trials and AI
- Abstract
Homologous recombination deficiency (HRD), caused by impaired homologous recombination repair (HRR), represents a clinically relevant molecular phenotype associated with genomic instability and therapeutic vulnerability. However, current HRD assessment relies mainly on tissue-based molecular assays, limiting its application in routine clinical practice. This study aimed to develop and validate a computed tomography (CT)-based deep radiomics signature (DRS) for noninvasive prediction of HRD status and to investigate its prognostic value and its association with outcomes after adjuvant chemotherapy in colorectal cancer (CRC). This multicenter retrospective study included 2065 patients with CRC from three hospitals in China. Among the 210 patients used for model training, 73 were classified as HRD and 137 as homologous recombination proficient (HRP). Radiomic and deep learning features were extracted from preoperative CT images. After feature selection, seven machine learning models were developed and compared. The optimal model was used to establish the DRS, which was further evaluated for HRD prediction and survival stratification in independent cohorts. Exploratory observational analyses examined whether associations between adjuvant chemotherapy and survival differed by DRS classification. Transcriptomic analysis was performed to explore the biological characteristics associated with the DRS-defined HRD phenotype. The DRS model demonstrated favorable discrimination for HRD status in the training, internal validation, and external validation cohorts, with AUCs of 0.873, 0.858, and 0.826, respectively. DRS classification effectively stratified overall survival (OS) and disease-free survival (DFS) across all cohorts. Multivariable Cox regression analysis showed that DRS remained independently associated with prognosis in CRC patients (all P < 0.001). Among patients with stage IIB-III CRC, adjuvant chemotherapy was associated with improved survival in the DRS-HRD subgroup, whereas no similar association was observed in the DRS-HRP subgroup. Transcriptomic analysis further showed that genes upregulated in DRS-HRD tumors were enriched in pathways related to cell cycle, DNA replication, and homologous recombination. The CT-based DRS noninvasively predicted the study-specific reference HRD label and stratified prognosis. In exploratory observational analyses, associations between adjuvant chemotherapy and survival differed by DRS group among patients with stage IIB-III disease.
Journal IF-equivalent: 8.6 (OpenAlex 2-year mean citedness, value as of 2026-11-03, retrieved 2026-11-05; not the official Clarivate IF)Reference: Lei X, Wang R, Li Z, Zhang R, Chen B, Zhou K, et al. Noninvasive imaging-based assessment of homologous recombination deficiency for risk stratification and adjuvant chemotherapy guidance in colorectal cancer: a multicenter study. J Transl Med. 2026 Nov 16 [Epub ahead of print]. doi:10.1186/s12967-026-09237-0.Checked: Abstract only - Abstract
Chemoresistance remains a major obstacle in colorectal cancer (CRC) treatment. In this study, we performed an integrative multi-omics analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, combined with machine learning approaches, to systematically investigate the UFMylation pathway in CRC. The E2 conjugating enzyme UFC1 was identified as a key determinant of chemotherapy sensitivity, with copy number amplification and elevated expression in tumors, particularly in chemotherapy-responsive patients. Single-cell transcriptomics revealed UFC1 enrichment in malignant epithelial cells, and its expression correlated with DNA damage response and apoptosis pathways. A LASSO-Cox risk model incorporating UFM1 pathway genes effectively stratified patient prognosis. Based on the UFC1 crystal structure, structure-based virtual screening was performed using TransformerCPI 2.0 against a million-scale compound libraries, followed by molecular docking, molecular dynamics simulations, and in vitro validation. The lead compound AK968 exhibited stable binding to UFC1 (ΔG = -25.07 kcal/mol), suppressed CRC cell proliferation, and synergistically enhanced 5-fluorouracil efficacy in a UFC1-dependent manner, with increased γ-H2AX foci formation indicating enhanced DNA damage accumulation. These findings identify UFC1 as a druggable effector of the UFMylation pathway in CRC chemotherapy stress and provide a framework integrating computational target identification, structure-based drug screening, and experimental validation for precision oncology.
Journal IF-equivalent: 9.8 (OpenAlex 2-year mean citedness, value as of 2026-11-04, retrieved 2026-11-05; not the official Clarivate IF)